The use of antioxidants in Friedreich’s ataxia treatment

Bibliography

• SCHULZ JB, DEHMER T, SCHOLS L et al.: Oxidative stress in patients with Friedreich ataxia. Neurology (2000) 55:1719–1721.
   PubMed Web of Science ®Google Scholar
• CHANTREL-GROUSSARD K, GEROMEL V et al.: Disabled early recruitment of antioxidant defenses in Friedreich's ataxia. Hum. Ma Genet. (2001) 10:2061–2067.
   PubMed Web of Science ®Google Scholar
• •This paper provides the first evidence that decreased frataxin hampers superoxide dismutase signalling in cells establishing a link between antioxidant signalling pathway and mitochondrial iron handling.
   Google Scholar
• PUCCIO H, KOENIG M: Friedreich ataxia: a paradigm for mitochondrial diseases. Carr. Opin. Genet. Dev. (2002) 12:272–277.
   PubMed Web of Science ®Google Scholar
• RUSTIN P, MUNNICH A, ROTIG A: Quinone analogs prevent enzymes targeted in Friedreich ataxia from iron-induced injury in vitro. Biofactors (1999) 9:247–251.
   PubMed Web of Science ®Google Scholar
• DURR A, COSSEE M, AGID Yet al.: Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl. Med. (1996) 335:1169–1175.
   Google Scholar
• HARDING AE: Friedreich's ataxia: a clinical and genetic study of 90 families with an analysis of early diagnostic criteria and intrafamilial clustering of clinicalfeatures. Brad) (1981) 104:589–620.
   Google Scholar
• HANAUER A, CHERY M, FUJITA R, DRIESEL AJ, GILGENKRANTZ S, MANDEL JL: The Friedreich ataxia gene is assigned to chromosome 9q13-q21 by mapping of tightly linked markers and shows linkage disequilibrium with D9S15. Am. J. Hum. Genet. (1990) 46:133–137.
   PubMed Web of Science ®Google Scholar
• CAMPUZANO V, MONTERMINI L, MOLTO MD et al: Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science (1996) 271:1423–1427.
   PubMed Web of Science ®Google Scholar
• ••The principle paper reporting theidentification of the FRDA disease-causing gene as being the frataxin encoding gene and the molecular rearrangement (a GAA repeat expansion in the first intron of the gene) occurring in95% of the FRDA patients.
   Google Scholar
• VETCHER AA, NAPIERALA M, IYER RR, CHASTAIN PD, GRIFFITH JD, WELLS RD: Sticky DNA, a long GAA.GAA.TTC triplex that is formed intramolecularly, in the sequence of intron 1 of the frataxin gene. J. Biol. Chem. (2002) 277:39217–39227.
   Google Scholar
• SAKAMOTO N, OHSHIMA K, MONTERMINI L, PANDOLFO M, WELLS RD: Sticky DNA, a self-associated complex formed at long GAA*TTC repeats in intron 1 of the frataxin gene, inhibits transcription. J. Biol. Chem. (2001) 276:27171–27177.
   PubMed Web of Science ®Google Scholar
• CAMPUZANO V, MONTERMINI L, LUTZ Y et al: Frataxin is reduced in Friedreich ataxia patients and is associated with mitochondrial membranes. Hum. Ma Genet. (1997) 6:1771–1780.
   PubMed Web of Science ®Google Scholar
• MUHLENHOFF U, RICHHARDT N, RISTOW M, KISPAL G, LILL R: The yeast frataxin homolog Yfhlp plays a specific role in the maturation of cellular Fe/ S proteins. Hum. MM. Genet. (2002) 11:2025–2036.
   PubMed Web of Science ®Google Scholar
• •The experiments reported in this study establish that frataxin function is tightly related to the synthesis of the Fe-clusters in the yeast cell, rather than intervening in the regulation of mitochondria iron transportation.
   Google Scholar
• DUBY G, FOURY F, RAMAZZOTTI A, HERRMANN J, LUTZ T: A non-essential function for yeast frataxin in iron-sulfur cluster assembly. Hum. MM. Genet. (2002) 11:2635–2643.
   PubMed Web of Science ®Google Scholar
• ROTIG A, DE LONLAY P, CHRETIEN D et al.: Aconitase and mitochondrial iron-sulphur protein deficiency in Friedreich ataxia. Nat. Genet. (1997) 17:215–217.
   PubMed Web of Science ®Google Scholar
• ••This is the first evidence that FRDA isindeed a mitochondrial disease resulting from generalised deficiency of the Fe-S proteins. It also described the tissue specificity of this deficiency that accounts for the fact that the mitochondrial origin of this disease had previously been overlooked.
   Google Scholar
• PARASKEVA E, HENTZE MW: Iron-sulphur clusters as genetic regulatory switches: the bifunctional iron regulatory protein-1. FEBS Lett. (1996) 389:40–43.
   PubMed Web of Science ®Google Scholar
• HENTZE MW, KUHN LC: Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc. Natl. Acad. Sci.USA (1996) 93:8175–8182.
   PubMed Web of Science ®Google Scholar
• PANTOPOULOS K, HENTZE MW: Activation of iron regulatory protein-1 by oxidative stress in vitro. Proc. Natl. Acad. Sci.USA (1998) 95:10559–10563.
   PubMed Web of Science ®Google Scholar
• HENTZE MW: Translational control by iron-responsive elements. Adv. Exp. Med. Biol. (1994) 356:119–126.
   PubMedGoogle Scholar
• RUSTIN P: Frataxin and mitochondrial iron. In: Molecular and Cellular Iron Transport. DM Templeton (Ed.) Marcel Dekker, Inc., New York/Basel (2002):255–272.
   Google Scholar
• BABCOCK M, DE SILVA D, OAKS R et al.: Regulation of mitochondrial iron accumulation by Yfhlp, a putative homolog of frataxin. Science (1997) 276:1709–1712.
   PubMed Web of Science ®Google Scholar
• FOURY F: Low iron concentration and aconitase deficiency in a yeast frataxin homologue deficient strain. FEBS Lett. (1999) 456:281–284.
   PubMed Web of Science ®Google Scholar
• RUSTIN P, VON KLEIST-RETZOW JC, CHANTREL-GROUSSARD K, SIDI D, MUNNICH A, ROTIG A: Effect of idebenone on cardiomyopathy in Friedreich's ataxia: a preliminary study. Lancet (1999) 354:477–479.
   PubMed Web of Science ®Google Scholar
• ••The very first evidence that idebenone can be used as an antioxidant to counteract the course of the cardiac disease associated with FRDA. Later confirmed by a series of open trials in Europe, this preliminary trial was based on a detailed study carried out on an in vitro system that first established the effectiveness of the drug to protect enzymes targeted in FRDA from Fe-triggered Fenton chemistry.
   Google Scholar
• ROTIG A, SIDI D, MUNNICH A, RUSTIN P: Molecular insights into Friedreich's ataxia and antioxidant-based therapies. Trends Mol. Med. (2002) 8:221–224.
   PubMed Web of Science ®Google Scholar
• PORTER KHJ: Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br. Hernatol. (1993) 85:393–400.
   PubMed Web of Science ®Google Scholar
• HAUSSE AO, AGGOUN Y, BONNET D et al.: Idebenone and reduced cardiac hypertrophy in Friedreich's ataxia. Heart (2002) 87:346–349.
   PubMed Web of Science ®Google Scholar
• NIENHUIS A: Vitamin C and iron. N Engl. Med. (1981) 304:170–171.
   PubMed Web of Science ®Google Scholar
• ERNSTER L, DALLNER G: Biochemical, physiological and medical aspects of ubiquinone function. Biochint. Biophys. Acta (1995) 1271:195–204.
   PubMed Web of Science ®Google Scholar
• GEROMEL V, DARIN N, CHRETIEN D et al.: Coenzyme Q(10) and idebenone in the therapy of respiratory chain diseases: rationale and comparative benefits. Mol. Genet. Metab. (2002) 77:21.
   PubMed Web of Science ®Google Scholar
• ROTIG A, APPELKVIST EL, GEROMEL V et al.: Quinone-responsive multiple respiratory-chain dysfunction due to widespread coenzyme Q10 deficiency. Lancet (2000) 356:391–395.
   PubMed Web of Science ®Google Scholar
• BUNSE M, BIT-AVRAGIM N, RIEFFLIN A et al.: Cardiac energetics correlates to myocardial hypertrophy in Friedreich's ataxia. Ann. Neurol. (2003) 53:121–123.
   PubMed Web of Science ®Google Scholar
• SCHOLS L, VORGERD M, SCHILLINGS M, SKIPKA G, ZANGE J: Idebenone in patients with Friedreich ataxia. Neurosci. Lett. (2001) 306:169–172.
   PubMed Web of Science ®Google Scholar
• SORENSEN L, EKSTRAND M, SILVA JPet al.: late-onset corticohippocampal neurodepletion attributable to catastrophic failure of oxidative phosphorylation in MILON mice. Neurosci. (2001) 21:8082–8090.
   Google Scholar
• ARTUCH R, ARACIL A, MAS A et al.: Friedreich's ataxia: idebenone treatment in early stage patients. Neuropediatrics (2002) 33:190–193.
   PubMed Web of Science ®Google Scholar
• LODI R, HART PE, RAJAGOPALAN B et al.: Antioxidant treatment improves in vivo cardiac and skeletal muscle bioenergetics in patients with Friedreich's ataxia. Ann. Neurol. (2001) 49:590–596.
   PubMed Web of Science ®Google Scholar